by Jen Hodson | Apr 1, 2019 | Press Release
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019CULVER CITY, CA – April 1, 2019 – NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced...